Cargando…

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies

The most common driver gene mutation in patients with non‐small‐cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR‐tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC patients with EGFR‐sensitive mutations have signif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Ying, Bai, Rilan, Cui, Jiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151140/ https://www.ncbi.nlm.nih.gov/pubmed/37005552 http://dx.doi.org/10.1111/1759-7714.14858

Ejemplares similares

Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
por: Li, Wenqian, et al.
Publicado: (2023)

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
por: Bai, Rilan, et al.
Publicado: (2022)

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer
por: Bai, Rilan, et al.
Publicado: (2021)

Precision Detection Technology: Equipping Precision Oncology with Wings
por: Bai, Rilan, et al.
Publicado: (2020)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
por: Bai, Rilan, et al.
Publicado: (2022)

Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis
por: Li, Wenqian, et al.
Publicado: (2021)

Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives
por: Bai, Rilan, et al.
Publicado: (2022)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
por: Lin, Chutong, et al.
Publicado: (2021)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Challenges of evaluating immunotherapy efficacy in solid tumors
por: Bai, Rilan, et al.
Publicado: (2019)

Targeted therapy combined with immunotherapy in patients with breast infiltrating ductal carcinoma with axillary lymph node metastasis of metaplastic SCC
por: Bai, Rilan, et al.
Publicado: (2022)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
por: Zhou, Shujie, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
por: Novak, Jennifer, et al.
Publicado: (2022)

Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
por: Liu, Rong, et al.
Publicado: (2022)

Refining precision cancer therapy in ALK-positive NSCLC
por: Lin, Jessica J., et al.
Publicado: (2019)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

The effect of coping strategy on quality of life in patients with NSCLC
por: Chabowski, Mariusz, et al.
Publicado: (2018)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
por: Boukansa, Sara, et al.
Publicado: (2023)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
por: Li, Jingpei, et al.
Publicado: (2020)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Examination of the effectiveness of local therapy for oligo‐recurrence of EGFR‐mutated NSCLC
por: Sonoda, Dai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kavlmu1abcsf2h8toinsn3rf1v